These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28534376)

  • 1. VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma.
    Shang D; Xian S; Han T; Li X; Liu Y
    J BUON; 2017; 22(2):500-507. PubMed ID: 28534376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VHL-TGFBI signaling is involved in the synergy between 5-aza-2'-deoxycytidine and paclitaxel against human renal cell carcinoma.
    Shang D; Xian S; Han T; Li X; Liu Y
    J BUON; 2017; 22(4):1038-1045. PubMed ID: 28952225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression.
    Shang D; Liu Y; Xu X; Han T; Tian Y
    Cancer Lett; 2011 Dec; 311(2):230-6. PubMed ID: 21880414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiling of the synergy of 5-aza-2'-deoxycytidine and paclitaxel against renal cell carcinoma.
    Han T; Shang D; Xu X; Tian Y
    World J Surg Oncol; 2012 Sep; 10():183. PubMed ID: 22950635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
    Shang D; Liu Y; Yang P; Chen Y; Tian Y
    Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
    Shang D; Ito N; Kamoto T; Ogawa O
    Urology; 2007 May; 69(5):1007-12. PubMed ID: 17482960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein tyrosine phosphatase ζ enhances proliferation by increasing β-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells.
    Shang D; Xu X; Wang D; Li Y; Liu Y
    World J Urol; 2013 Dec; 31(6):1547-54. PubMed ID: 23588815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
    Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
    Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibitory effects of 5-aza-2'-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways.
    Shang D; Li G; Zhang C; Liu Y
    Biochem Cell Biol; 2022 Apr; 100(2):115-124. PubMed ID: 34890285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Hippel-Lindau tumor suppressor gene-dependent mRNA stabilization of the survival factor parathyroid hormone-related protein in human renal cell carcinoma by the RNA-binding protein HuR.
    Danilin S; Sourbier C; Thomas L; Rothhut S; Lindner V; Helwig JJ; Jacqmin D; Lang H; Massfelder T
    Carcinogenesis; 2009 Mar; 30(3):387-96. PubMed ID: 19056930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.
    Ivanov SV; Ivanova AV; Salnikow K; Timofeeva O; Subramaniam M; Lerman MI
    Biochem Biophys Res Commun; 2008 Jun; 370(4):536-40. PubMed ID: 18359287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
    Yuen JS; Akkaya E; Wang Y; Takiguchi M; Peak S; Sullivan M; Protheroe AS; Macaulay VM
    Mol Cancer Ther; 2009 Jun; 8(6):1448-59. PubMed ID: 19509240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
    Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
    Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
    Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
    Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
    Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
    J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of nuclear factor kappa B in renal cell carcinoma.
    Morais C; Gobe G; Johnson DW; Healy H
    Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
    Peruzzi B; Athauda G; Bottaro DP
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VHL enhances 9-cis-retinoic acid treatment by down-regulating retinoid X receptor α in renal cell carcinomas.
    Wang F; Wang LS; Gao YH; Yao XD
    Biochem Biophys Res Commun; 2020 Mar; 523(2):535-541. PubMed ID: 31928714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.